InvestorsHub Logo
Followers 483
Posts 61598
Boards Moderated 14
Alias Born 09/20/2001

Re: Paulness post# 9592

Tuesday, 06/19/2018 2:21:10 PM

Tuesday, June 19, 2018 2:21:10 PM

Post# of 9951
This is good news, but I do wish there was more discussion of the science here.


Provectus’ lead investigational oncology drug product, PV-10, the first small molecule oncolytic immunotherapy, can induce immunogenic cell death. PV-10 is undergoing clinical study for adult solid tumor cancers, like melanoma and cancers of the liver, and preclinical study for pediatric cancers.



Not being in the field I'm not completely sure what the above means. What is the advantage of being "small molecule" and how is this better than other methods?

Anyone care to discuss? I have some ideas but not enough expertise in the field to speak with authority.




In Peace, In War

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PVCT News